Share Name Share Symbol Market Type Share ISIN Share Description
Dechra Pharmaceuticals Plc LSE:DPH London Ordinary Share GB0009633180 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  40.00 1.16% 3,498.00 223,122 16:35:21
Bid Price Offer Price High Price Low Price Open Price
3,478.00 3,484.00 3,504.00 3,356.00 3,474.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 608.00 74.00 51.33 68.1 3,791
Last Trade Time Trade Type Trade Size Trade Price Currency
18:14:27 O 1,596 3,476.604 GBX

Dechra Pharmaceuticals (DPH) Latest News

More Dechra Pharmaceuticals News
Dechra Pharmaceuticals Investors    Dechra Pharmaceuticals Takeover Rumours
Smart Money!
DPH is a large holding in the following funds:
 Fund  Percentage of Fund  Last Updated 

Dechra Pharmaceuticals (DPH) Discussions and Chat

Dechra Pharmaceuticals Forums and Chat

Date Time Title Posts
18/5/202210:55Dechra Pharmaceuticals Plc550
10/3/201216:10Dechra with Charts9
10/3/201216:10Dechra Pharmaceuticals PLC1

Add a New Thread

Dechra Pharmaceuticals (DPH) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2022-07-01 17:14:403,476.601,59655,486.60O
2022-07-01 17:09:543,454.892,85598,637.17O
2022-07-01 16:57:383,497.481575,491.04O
2022-07-01 16:57:153,475.181,44850,320.56O
2022-07-01 16:53:283,451.777241.62O
View all Dechra Pharmaceuticals trades in real-time

Dechra Pharmaceuticals (DPH) Top Chat Posts

Dechra Pharmaceuticals Daily Update: Dechra Pharmaceuticals Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker DPH. The last closing price for Dechra Pharmaceuticals was 3,458p.
Dechra Pharmaceuticals Plc has a 4 week average price of 3,066p and a 12 week average price of 3,066p.
The 1 year high share price is 5,525p while the 1 year low share price is currently 3,066p.
There are currently 108,388,305 shares in issue and the average daily traded volume is 241,048 shares. The market capitalisation of Dechra Pharmaceuticals Plc is £3,791,422,908.90.
roguetraderuk: st, the ones you mention are all high multiple names esp for the uk mkt. when price of money is repriced so are these. on top of that youve got extra risk repricing from the back end of covid and the war which is leading to a global economic slowdown. ive never been able to buy halma over the years, i always ended up picking up something similarly positioned re growth. most recently during the covid drop i weighed up halma and ashtead, plumping for the latter eventually. now out of that and looking for a re entry at some point this year. but the point is the high multiple names dont tend to work when yields are going up. eventually they will stop and thats the time to step in imo.
steeplejack: I suppose Dechra is something of a covid play in that pet ownership increased significantly during the epidemic.Will owners abandon their furry four legged friends now the epidemic is tailing off?Unlikely i would have thought.This company is an obvious beneficiary of sterling weakness of course.Sterling has weakened over ten cents or some 9% since the interim stage but the market is ignoring that.Sadly,Dechra is vulnerable to general disillusionment with equities along with the likes of Croda,Halma etc which similarly still well up on where they were trading a couple of years ago.There's a strong case for simply shoving off for the Summer and ignoring equity markets.There are too many negative headwinds,algorithmic trading dominating day to day trading.It's impossible to rationalise some of the price moves dictated as they are by a simple deleveraging of markets.
steeplejack: Ah there’s a sale of 92/- odd….that might explain it.Pretty lousy price achieved. So on reflection,it looks like some fund manager found himself compelled to sell stock on the last trading day before Easter as a result perhaps of redemption requirements,a sudden bout of nerves,a damascene experience or simple stupidity.For whatever reason selling some 4 million quids worth of Dechra on the afternoon before a bank holiday in a quiet market smacks of irresponsibilityR30;.. but who knows what the future holds.
km18: Dechra Pharmaceuticals issued its HY Financial Report this morning. Reported Group revenue for the period increased by 15.9% to £332.4m at Constant Exchange Rate (CER). Underlying operating profit growth was 22.0% with underlying operating margin improving by 140 bps to 28.2%. Underlying diluted EPS growth was 24.0% to 64.01p and the interim dividend increased by 8.0% to 12 pence. So more robust growth and more profitable growth. The business has been growing briskly and profitably for many years now and looks set to continue this pattern in FY22 as well. Unsurprisingly investors have already bought into the story, valuation is rich with forward PE ratio around 31 and bottom quartile for the Pharma sector. The share price is also currently in a 30%+ correction and still falling after a powerful post-Covid rally. DPH is a very good company delivering persistent and robust growth, but there is no rush to buy. Monitor for the time being.... ...from WealthOracleAM
spyder: I have been following Dechra for years, but only just bought some shares. FWIW, then look oversold to me, the pandemic increase in pet numbers (both in the UK and US) together with increased veterinary activity is not ‘over’, it will be sustained. The only thing that IS over is the onetime jump in the growth rate, I expect now to see a resumption of more normal rates of growth, albeit from a higher base. The share are effectively below pre-pandemic multiples and that makes no sense to me.
spyder: Anyone following this share? Results on Monday.
lindowcross: I'm not a follower or believer in chart analysis but it's not hard to see from the graph that since 2018 there has been 6-7 "dips" in the share price. Despite this the overall trajectory remains upward. Best to buy on the dips with a successful company like this.
lindowcross: Dechra (credit Emma Powell in The Times) Dechra can’t afford to show any signs of weakness. A boom in pet ownership and the amount that people are willing to fork out for their animals has supercharged revenue and profit growth for the pet pharmaceuticals specialist. That’s left the shares with an eye-watering forward price-earnings ratio of 44 — a valuation that’s near a record high. It’s only natural, then, that investors applauded the company’s latest reassurance that market demand, particularly in the United States, had remained strong since the end of June. In an animal health market dominated by large players focused on mass-market products such as flea and worming treatments, Dechra has carved out a niche, prescription-only drugs business primarily for dogs, cats and horses. It has three avenues for profit growth: new product development; bolt-on acquisitions; and expansion into markets where emerging wealth is willing to spend more on pets. SIGN UP FOR OUR ... Weekly newsletter News, inspiration and advice for business leaders from British entrepreneurs Lockdown switched profit growth into a higher gear — “companion animal” products, which account for just under three quarters of group turnover, boosted revenue by about a quarter last year — but further growth faces a challenge: the (quite likely) chance that the attractions of pet ownership during lockdown subsides. Zoetis, the market leader in America, has already flagged a slowdown in the rate of demand during the second half of the year. R&D spending is typically steady as a proportion of revenue at about 6.5 per cent. But selling and general operating expenses should return to 60 per cent to 70 per cent of pre-pandemic levels as sales reps get back on the road. Liberum forecasts about 80 basis points of margin erosion this year, against an underlying operating margin of 26.7 per cent last year. There’s also the threat of supply chain disruption. Products in short supply include antibiotics, primarily sourced from China and used in the manufacture of treatments. Dechra is holding more inventory in an attempt to stave off the threat of running out of stock. However, manifold risks aren’t reflected in the shares, which remain priced for perfection. ADVICE Avoid WHY Shares exposed to a sell-off if there are any hints of weakness in earnings. Ends (naturally, I don't agree! and am holding) ..............
steeplejack: I don't think these figures are disappointing.Its an opportunity for the marketmakers to shake out some loose stock.They are well aware that a stock (that has had such a prolonged run) will be subject to top slicing since portfolio weightings have nudged higher due to the stocks outperformance.There's always a tendency to interpret the markets share price moves as justified and correct.This is patently wrong,certainly on the day of results.While noting a high forward multiple,i'm much more cognisant of the PEG ratio.As Warren Buffet said,he really wouldn't mind if they closed stockmarket quotes for a couple of years,he's in for the long term.An attitude that reflects his personal wealth perhaps but the message is instructive.
whatja: DPH is being touted for a potential promotion to the FTSE100. This is because BHP is delisting and JET is reclassified as non-UK because most trading is now is US following a takeover.
Dechra Pharmaceuticals share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Dechra Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220702 14:21:28